NLS Sanofi

The global, randomized, double-blind placebo-controlled Phase 3 study will include more than 35,000 volunteers aged 18 and older from several countries, including sites in the US, Asia, Africa, and Latin America. The primary endpoint of the study is the prevention of symptomatic COVID-19 in SARS-CoV-2 naïve adults, with secondary endpoints being the prevention of severe […]

The company notes the announcement of Sanofi’s agreed acquisition of Ablynx and confirms that it will not be making a revised proposal. On 8 January, Novo Nordisk announced its proposal to acquire Ablynx for up to EUR 30.50 per share in cash, consisting of EUR 28.00 upfront and EUR 2.50 in Contingent Value Rights. Novo Nordisk […]

Sanofi will acquire the Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), just a few days after the company turned down Novo Nordisk’s bid. The acquisition is Sanofi’s second major takeover deal this month following its acquisition of Bioverativ. “Since our founding in 2001, our team has been focused on unlocking the power of […]

Antaros Medical, has entered into a research agreement with  SANOFI. The project seeks to increase the understanding of the activity of certain incretins and underscores the vital role Antaros Medical plays as a trusted partner to major drug manufacturers. “The Antaros team has an impressive track record in early clinical experimentation and clinical functional imaging. […]

Gubra have announced the launch of a new research collaboration agreement with Sanofi focusing on the discovery of gut peptides. The new research program initiated between Gubra and Sanofi builds upon the  established research consortium between Gubra, Gentofte Hospital and the University of Copenhagen partly funded by the Danish National Advanced Technology foundation. “We are […]